Get the Stockscreener App
285.42
0.71%
2.02
Abbvie Inc stock is traded at $285.42, with a volume of 5.64M.
It is up +0.71% in the last 24 hours and up +8.73% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$283.40
Open:
$283.61
24h Volume:
5.64M
Relative Volume:
0.96
Market Cap:
$504.37B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
140.78
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+3.24%
1M Performance:
+8.73%
6M Performance:
+36.57%
1Y Performance:
+25.81%
1-Day Range:
$282.95
$286.64
1-Week Range:
$273.70
$291.40
52-Week Range:
$190.75
$291.40
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
285.42 | 504.37B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,257.03 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.56 | 615.87B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
145.95 | 360.08B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.62 | 286.29B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance
5 Stock Ideas for Your Short List - TradingView
5 Stock Ideas for Your Short List - Zacks Investment Research
Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00 - ad-hoc-news.de
AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance
Form 4 AbbVie Inc For: 16 October By Investing.com - Investing.com Nigeria
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
Abbvie Inc. Announces Appointment of John M. Carethers as Director and Member of Public Policy and Sustainability Committee - www.marketscreener.com
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF - The Motley Fool
Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot - Bloomberg Law News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
AbbVie’s Q3 2026 Earnings: What to Expect - Barchart.com
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today. - Barron's
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis - TradingKey
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
A Look at AbbVie Inc (ABBV) After 2.4% Decline -- GF Value $222. - GuruFocus
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says - Yahoo Finance
AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins - Yahoo Finance
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
HSBC Raises AbbVie Price Target to $315 on Immunology Drug Label Expansions - NAI500
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold? - Yahoo Finance
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. - Yahoo Finance
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says - marketscreener.com
Abbvie-Genmab Epkinly data signal first-line filing for DLBCL - BioWorld News
AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770 - AD HOC NEWS
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
UBS reiterates Abbvie stock rating on positive cancer trial data By Investing.com - Investing.com Canada
Should You Buy AbbVie Stock Before Oct. 30? - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - 24/7 Wall St.
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug - Sharecast.com
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield - The Motley Fool
BofA raises target for AbbVie stock from USD 282.00 to USD 289.00 - AD HOC NEWS
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbvie Inc Stock (ABBV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
| NICHOLAS DONOGHOE | Officer |
Aug 14 '26 |
Proposed Sale |
250.00 |
32,710 |
8,177,500 |
0 |
| ROBERT J ALPERN | Director |
May 26 '26 |
Proposed Sale |
214.00 |
13,000 |
2,781,991 |
0 |
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
| David R. Purdue | Officer |
Mar 04 '26 |
Proposed Sale |
233.56 |
5,230 |
1,221,519 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
234.39 |
18,668 |
4,375,549 |
4,619 |
| PERRY C SIATIS | Officer |
Mar 02 '26 |
Proposed Sale |
234.39 |
18,668 |
4,375,585 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Option Exercise |
172.62 |
22,381 |
3,863,458 |
60,518 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Sale |
230.00 |
22,381 |
5,147,630 |
38,137 |
| PERRY C SIATIS | Officer |
Feb 25 '26 |
Proposed Sale |
230.00 |
22,381 |
5,147,630 |
0 |
0.90%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):